一批含量不合格阿莫西林颗粒测定结果分析

目的 针对一批含量不合格阿莫西林颗粒进行结果分析。方法 高效液相色谱法测定阿莫西林颗粒含量及含量均匀度，并对颗粒是否研磨成粉末作不同处理。结果 6次含量测定结果相差较大；颗粒研磨成粉末对含量测定结果没有显著性影响（P〉0．05），但可使测定结果的相对标准偏差（RSD）较小；含量均匀度检查示每包实际含量与标示量相差很大（A＋1．80S〉15．0），且单包含量的多少对应不同的色谱图谱。结论 该批阿莫西林颗粒含量不合格是含量均匀性较差所致，厂家用两种原料生产同批产品可能是其根本原因。     

Development and validation of a simple HPLC method for simultaneous in vitro determination of amoxicillin and metronidazole at single wavelength

A simple, rapid, sensitive and robust reversed phase-HPLC method was developed and validated to measure simultaneously the amount of amoxicillin and metronidazole at single wavelength (254 nm) in order to assess drug release profiles and drug-excipients compatibility studies for a new floating-sustained release tablet formulation and its subsequent stability studies. An isocratic elution of filtered sample was performed on C18 column with buffered mobile phase (pH 4.0) and UV detection at 254 nm. Quantification was achieved with reference to the external standards. The linearity for concentrations between 0.15 and 600 microg/ml for amoxicillin and 0.13 and 300 microg/ml for metronidazole were established. Intra and inter-day precision were less than 2.5%. The limits of detection (LOD) and quantification were 0.05 and 0.15 microg/ml for amoxicillin and 0.10 and 0.13 microg/ml for metronidazole. The determination of the two active ingredients was not interfered by the excipients of the products. Samples were stable in the release media (37 degrees C) and the HPLC injector at least for 12 h.     

Simultaneous determination of amoxicillin and clavulanic acid in human plasma by isocratic reversed-phase HPLC using UV detection

A simple, rapid and sensitive isocratic reversed phase HPLC method with UV detection using internal standard has been developed and validated for simultaneous determination of amoxicillin and clavulanic acid in human plasma. The assay enables the measurement of amoxicillin and clavulanic acid for therapeutic drug monitoring with a minimum quantification limit of 15 and 30 ng ml(-1), respectively. The method involves simple, one-step extraction procedure and analytical recovery was complete. The separation was carried out in reversed-phase conditions using a Chromolith Performance (RP-18e, 100 mm x 4.6mm) column with an isocratic mobile phase consisting of 0.02 M disodium hydrogen phosphate buffer-methanol (96:4, v/v) adjusted to pH 3.0. The wavelength was set at 228 nm. The coefficients of variation for inter-day and intra-day assay were found to be less than 9.0%.     

三联疗法治疗肝源性溃疡患者疗效观察

目的观察奥美拉唑、克拉霉素、阿莫西林三联疗法治疗肝源性溃疡的疗效。方法活动性胃溃疡患者100例,分为肝源性溃疡(A组)50例和非肝源性溃疡(B组)50例,A组用奥美拉唑20mg+克拉霉素500mg+阿莫西林1000mg三联治疗,B组单用奥美拉唑20mg治疗,观察两组疗效、症状缓解率、肝功能Child分级与溃疡愈合率关系。结果治疗4周后,B组总有效率为86.1%,高于A组58.3%(χ2=4.51,P<0.05);ChildA级4、8周溃疡愈合率明显高于ChildB级和ChildC级(4周:χ2=4.12,P<0.05,χ2=6.78,P<0.01;8周:χ2=4.36,P<0.05,χ2=6.81,P<0.01);疗程结束后A组症状缓解率86.0%,低于B组94.0%(χ2=4.01,P<0.05)。结论肝源性溃疡药物治疗效果较差。可能需要延长疗程或辅之以其他方法 。     

两种三联法治疗十二指肠溃疡并幽门螺杆菌感染的对比研究

目的：评价埃索美拉唑、阿莫西林、左氧氟沙星及埃索美拉唑、克拉霉素、左氧氟沙星两种三联法7d疗程根除十二指肠球部溃疡合并幽门螺杆菌感染的疗效。方法：将92例经电子胃镜诊断为十二指肠球部溃疡、14碳-尿素呼气试验（14C-UBT）Hp阳性患者随机分为两组,即治疗组48例给予埃索美拉唑20mg、阿莫西林1000mg、左氧氟沙星200mg口服,2次/d,共7d;对照组44例给予埃索美拉唑20mg、克拉霉素500mg、左氧氟沙星200mg口服,2次/d,共7d;停服药4周后复查胃镜及14碳-尿素呼气试验,观察溃疡愈合情况以及幽门螺杆菌根除率。结果：治疗组及对照组幽门螺杆菌根除率及十二指肠球部溃疡愈合率分别为93.75%、93.18%和97.92%、97.73%,差异均无统计学意义（P〉0.05）。结论：两种新的三联法治疗方案在治疗十二指肠球部溃疡并Hp感染均有效,不但为探讨多种根除Hp治疗方式提供了临床依据,同时可作为根除十二指肠溃疡Hp再感染复发的一线治疗或失败后的补救治疗方案。     

三种药物联合治疗HP阳性胃十二指肠溃疡的疗效观察

目的探讨埃索美拉唑、阿莫西林及克拉霉素联合应用治疗幽门螺旋杆菌（HP）阳性的胃十二指肠溃疡的临床效果。方法将2008年1月-2009年6月间在我院住院治疗的HP阳性的胃十二指肠溃疡患者50例,随机分为观察组和对照组,观察组给予埃索美拉唑、阿莫西林及克拉霉素联合应用治疗,对照组给予奥美拉唑、阿莫西林及左氧氟沙星联合应用,观察疗效。结果治疗组总有效率为96．00％,对照组为80．00％,两组比较差异具有显著性IP〈0．05）。治疗组疼痛消失时间为（1．56±0．25）d,对照组为（2．34±0．24）d,治疗组疼痛消失时间明显短于对照组,两组比较差异具有显著性垆〈0．05）。治疗组HP根除率为94．74％,对照组为89．47％,两组比较差异无显著性（P〉0．05）。两组在治疗过程中均未发生明显的不良反应。结论埃索美拉唑、阿莫西林及克拉霉素联合应用治疗HP阳性的胃十二指肠溃疡效果更好,值得应用。     

左氧氟沙星与阿奇霉素联用阿莫西林克拉维酸钾治疗社区获得性肺炎对照分析

目的比较左氧氟沙星与阿奇霉素联用阿莫西林克拉维酸钾治疗社区获得性肺炎的临床疗效、安全性、成本-效果。方法将80例门诊诊治的社区获得性肺炎轻．中度患者,随机分为左氧氟沙星治疗组与阿奇霉素联用阿莫西林克拉维酸钾对照组,观察两组患者的临床疗效,不良反应、成本-效果比较。结果治疗组43例患者,痊愈35例（81．4％）,显效4例（9．3％）,总有效率为90．7％,不良反应率为9．3％,平均抗生素费用为52．5元;对照组37例患者,痊愈30例（81．1％）,显效4例（10．8％）,总有效率为91．9％,不良反应率为8．1％,平均抗生素费用为90．9元。结论左氧氟沙星与阿奇霉素联用阿莫西林克拉维酸钾门诊治疗社区获得性肺炎的临床疗效、安全性差异无统计学意义,成本-效果比较,左氧氟沙星优于阿奇霉素联用阿莫西林克拉维酸钾。